Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H12BNO4 |
Molecular Weight | 209.007 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC1=CC=C(C=C1)B(O)O)C(O)=O
InChI
InChIKey=NFIVJOSXJDORSP-QMMMGPOBSA-N
InChI=1S/C9H12BNO4/c11-8(9(12)13)5-6-1-3-7(4-2-6)10(14)15/h1-4,8,14-15H,5,11H2,(H,12,13)/t8-/m0/s1
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0015828 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24186331 |
|||
Target ID: GO:0015823 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24186331 |
PubMed
Title | Date | PubMed |
---|---|---|
Neutron capture therapy of intracerebral melanoma: enhanced survival and cure after blood-brain barrier opening to improve delivery of boronophenylalanine. | 2002 Mar 1 |
|
Prognostic and therapeutic indicator of fluoroboronophenylalanine positron emission tomography in patients with gliomas. | 2003 Dec 1 |
|
Biodistribution of a carborane-containing porphyrin as a targeting agent for Boron Neutron Capture Therapy of oral cancer in the hamster cheek pouch. | 2003 Mar |
|
Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine. | 2003 Mar-Apr |
|
Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation. | 2003 Mar-Apr |
|
A critical assessment of boron neutron capture therapy: an overview. | 2003 Mar-Apr |
|
The early successful treatment of glioblastoma patients with modified boron neutron capture therapy. Report of two cases. | 2003 Nov |
|
Accumulation of boron in human malignant glioma cells in vitro is cell type dependent. | 2004 Jul |
|
The effect of dexamethasone on the uptake of p-boronophenylalanine in the rat brain and intracranial 9L gliosarcoma. | 2004 Nov |
|
Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent. | 2004 Nov |
|
Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors. | 2004 Sep 1 |
|
Boron neutron capture therapy of cancer: current status and future prospects. | 2005 Jun 1 |
|
Impact of intra-arterial administration of boron compounds on dose-volume histograms in boron neutron capture therapy for recurrent head-and-neck tumors. | 2006 Dec 1 |
|
Homogeneous boron targeting of heterogeneous tumors for boron neutron capture therapy (BNCT): chemical analyses in the hamster cheek pouch oral cancer model. | 2006 Oct |
|
Early effects of boron neutron capture therapy on rat glioma models. | 2007 |
|
Boron neutron capture therapy at the crossroads: challenges and opportunities. | 2009 Jul |
|
Boronophenylalanine uptake in C6 glioma model is dramatically increased by L-DOPA preloading. | 2009 Jul |
|
Aryl boronic acid inhibition of synthetic melanin polymerization. | 2010 Aug 1 |
|
Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2/Bax. | 2010 Dec 2 |
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
76410-58-7
Created by
admin on Sat Dec 16 01:06:17 GMT 2023 , Edited by admin on Sat Dec 16 01:06:17 GMT 2023
|
PRIMARY | |||
|
150315
Created by
admin on Sat Dec 16 01:06:17 GMT 2023 , Edited by admin on Sat Dec 16 01:06:17 GMT 2023
|
PRIMARY | |||
|
SUB33568
Created by
admin on Sat Dec 16 01:06:17 GMT 2023 , Edited by admin on Sat Dec 16 01:06:17 GMT 2023
|
PRIMARY | |||
|
JSM63LV5MD
Created by
admin on Sat Dec 16 01:06:17 GMT 2023 , Edited by admin on Sat Dec 16 01:06:17 GMT 2023
|
PRIMARY | |||
|
DTXSID70227242
Created by
admin on Sat Dec 16 01:06:17 GMT 2023 , Edited by admin on Sat Dec 16 01:06:17 GMT 2023
|
PRIMARY | |||
|
100000127519
Created by
admin on Sat Dec 16 01:06:17 GMT 2023 , Edited by admin on Sat Dec 16 01:06:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)